Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria and tetanus toxoids and pertussis, hepatitis B, poliovirus, and Haemophilus influenzae type b vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Diphtheria and tetanus toxoids and pertussis, hepatitis B, poliovirus, and Haemophilus influenzae type b vaccine (DTPw-HBV-IPV/Hib) is an investigational hexavalent combination vaccine developed by GSK Biologicals. This specific formulation is distinguished by its use of whole-cell pertussis (DTPw) antigens, rather than the acellular pertussis (DTaP) components found in many modern hexavalent vaccines like Infanrix Hexa. The vaccine also contains diphtheria and tetanus toxoids, hepatitis B surface antigen (HBsAg), inactivated poliovirus (IPV) types 1, 2, and 3, and Haemophilus influenzae type b (Hib) conjugate antigens. It is designed to provide active immunization against six major childhood diseases: diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Hib-induced infections. Clinical development has focused on its use as a booster dose in toddlers who have previously received primary poliovirus vaccination.
- Other names
- hexavalent DTPw-HBV-IPV/Hib vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)γδ TCR (T-cell receptor)Diphtheria toxinHBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on diphtheria and tetanus toxoids and pertussis, hepatitis B, poliovirus, and Haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria and tetanus toxoids and pertussis, hepatitis B, poliovirus, and Haemophilus influenzae type b vaccine.